FGFernanda M. Garcia‐Garcia

Fernanda M. Garcia‐Garcia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fernanda M. Garcia‐Garcia has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Values, preferences, and treatment burden for initiation of GLP-1 receptor agonists, SGLT-2 inhibitors, tirzepatide, and finerenone in adults with type 2 diabetes: systematic review

    by Daniela C González-Cruz, Mariano Garcia-Campa, Pablo José Moreno-Peña, Andres Avalos-Bishop, Dulce María Manzanares-Gallegos, Fernanda M Garcia-Garcia, Jan Alejandro Montiel Labastida, José Gerardo González-González, Arnav Agarwal, Veena Manja, et al.

  • Alopecia Areata Associated With Bimekizumab Therapy

    by Fernanda M. Garcia‐Garcia, Maria Fernanda Ortiz‐Nuño, Héctor Teodoro Rios‐Bazaldua, Rodolfo Franco‐Marquez, Jose Antonio Garcia‐Muñiz, Jorge Larrondo, Cassandra Michele Skinner‐Taylor, Dionicio Angel Galarza‐Delgado, Jesus Alberto Cardenas‐De la Garza


  • Relationship Between Nail Psoriasis Severity Index and Cardiovascular Risk Assessed by 10 Cardiovascular Risk Calculators

    by Maria F. Elizondo‐Benitez, Andrea L. Guajardo‐Aldaco, Fernanda M. Garcia‐Garcia, Dionicio A. Galarza‐Delgado, Jose R. Azpiri‐Lopez, Rosa I. Arvizu‐Rivera, Jesus A. Cardenas‐De la Garza, Valeria Gonzalez‐Gonzalez, Iris J. Colunga‐Pedraza

    Objective: To determine the relationship between Nail Psoriasis Severity Index (NAPSI) and cardiovascular risk (CVR) assessed by 10 CVR calculators. Methods: Cross‐sectional, observational, and comparative study of psoriatic arthritis (PsA) patients aged 30–75, classified according to established diagnostic criteria. The NAPSI was assessed, classifying patients into two groups: with (≥ 1) and without (< 1) nail involvement. The CVR was evaluated through: Framingham (FRS) lipids and body mass index (BMI), American College of Cardiology/American Heart Association‐ Atherosclerotic Cardiovascular Disease 2013 (ACC/AHA ASCVD 2013), Systematic Coronary Risk Evaluation (SCORE), SCORE 2, SCORE‐Older Persons (OP), QRISK3, Reynolds Risk Score (RRS), Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) atherosclerotic cardiovascular disease (ASCVD) and PREVENT Heart Failure (HF) calculator. Group distribution was assessed using the Kolmogorov–Smirnov test. Comparisons were conducted accordingly with Chi‐Squared, T‐Student, U‐Mann–Whitney, and Kruskal–Wallis tests. Correlations were performed using Spearman's rho. Statistical significance was set at p ≤ 0.05. Results: Seventy‐one patients with PsA were included, 31 with nail involvement and 40 without. CVR score was higher in PsA patients with nail involvement using SCORE (2.0 (1.0–3.7) versus 1.0 (0.0–2.0), p = 0.02). Regarding CVR, positive correlations were found between NAPSI and the following calculators: ACC/AHA ASCVD 2013 (Spearman's rho = 0.202, p = 0.045), FRS BMI (Spearman's rho = 0.229, p = 0.027), SCORE (Spearman's rho = 0.344, p = 0.002), PREVENT ASCVD (Spearman's rho = 0.198, p = 0.049), and PREVENT HF (Spearman's rho = 0.291, p = 0.007). Conclusions: A NAPSI ≥ 1 score is related to higher CVR assessed through SCORE and positively correlates with ACC/AHA, PREVENT TM ASCVD, and PREVENT HF.